Breakthrough Science for Severe Viral Lung Infections
We are a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta (IFN-β) for the treatment of severe viral lung infections as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs.
Not All Antivirals Are the Same
Host Directed, broad-spectrum antivirals
Host Directed is Synairgen's new podcast series that explores the need for broad-spectrum antivirals to treat severe respiratory infections. In Episode 1, Not All Antivirals Are the Same, Professor Tom Wilkinson from the University of Southampton and Vicki Tear, Vice President, Non-Clinical Operations, Synairgen, discuss how antiviral agents work on viruses and the potential benefits of broad-spectrum host-directed antivirals. Episode 2 includes Professor Ratko Djukanovic, Professor of Medicine at University of Southampton and Richard Marsden, CEO of Synairgen, continuing the discussion with a focus on understanding the broad-spectrum antiviral protein, IFN-β.
Episode 1: Not All Antivirals Are the Same
Professor Tom Wilkinson from the University of Southampton and Vicki Tear, Vice President, Non-Clinical Operations, Synairgen, discuss how antiviral agents work on viruses and the potential benefits of broad-spectrum host-directed antivirals.
Episode 2: What is IFN-β and How Does It Work?
Professor Ratko Djukanovic, Professor of Medicine at University of Southampton and Richard Marsden, CEO of Synairgen, continue to explore antivirals with a discussion focused on understanding the broad-spectrum antiviral protein, IFN-β .
The Need
Viruses that cause severe respiratory infections lead to the hospitalisation of more than 2 million people in the US alone each year.
There are currently no broad-spectrum antivirals approved for use in patients who become hospitalised with these severe respiratory viral infections including SARS-CoV-2, complicated influenza, RSV, adenovirus, parainfluenza and rhinoviruses.
source: IQVIA
Estimated 2m+
people in US hospitalised annually due to severe respiratory viral infections
source: HCUP~60k
The average cost in the US of a hospitalisation caused by severe respiratory viral infections requiring invasive mechanical ventilation
sources: CDC